Terkko Navigator / Hematology/ Feeds

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

Frontline Science: Late CD27 stimulation promotes IL‐7Rα transcriptional re‐expression and memory T cell qualities in effector CD8+ T cells

BOK promotes erythropoiesis in a mouse model of myelodysplastic syndrome

Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia

Frontline Science: Late CD27 stimulation promotes IL‐7Rα transcriptional re‐expression and memory T cell qualities in effector CD8+ T cells

HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study.

The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia

Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study

Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone.

Antihyperglycemic effect of the aqueous extract of Foeniculum vulgare in normal and streptozotocin-induced diabetic rats.

Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS

Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia

The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability

How do I audit intraoperative blood component utilization in cardiac surgery?

An automated motivational interview promotes donation intention and self‐efficacy among experienced whole blood donors

Loss of KDM6A confers drug resistance in acute myeloid leukemia

Efficacy of a strict surveillance policy towards inappropriateness of plasma transfusion

von Willebrand factor promotes wound healing

Eltrombopag: wielding a double-edged sword?

B-1 progenitor acute lymphoid leukemia

The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing

Acalabrutinib for mantle cell lymphoma

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Clinical and immunological features in a cohort of patients with partial DiGeorge syndrome followed at a single center

Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells

Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background

With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study

Archeogenetics of F11 p.Cys38Arg: a 5400-year-old mutation identified in different southwestern European countries

HTLV-1-associated adult T-cell leukemia/lymphoma with disseminated strongyloidiasis

Unusual case of a myelodysplastic syndrome with novel inv(5)(q15q33)

Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Is There a Role for Dose Modification of TKI Therapy in CML?

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders

The microbiome and cancer for clinicians

Role of long non-coding RNAs in lymphoma: A systematic review and clinical perspectives

Impact of cold storage on platelets treated with Intercept pathogen inactivation

Association of alpha hemoglobin–stabilizing protein (AHSP) gene mutation and disease severity among HbE—beta thalassemia patients

Current role of high dose chemotherapy in the management of multiple myeloma

CLL and CML sometimes meet and circulate together

Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

Adoptive cell therapy for acute myeloid leukemia

A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents